Moat: Narrow

jbh

JBH: Electronics Giant - Navigating the Amazon Storm

Updated 11 Oct 2025

Market-leading retailer with 35.2% ROIC trading at fair value $67.02, facing e-commerce disruption whilst maintaining exceptional operational efficiency and 25% market share.

View note
iri

IRI: Software Monitoring Specialist - Transformation or Termination?

Updated 8 Oct 2025

Speculative transformation play trading at 76% discount to $0.74 fair value. Strong balance sheet ($40.6m net cash) provides runway but execution risk substantial with 30% management track record.

View note
ipg

IPG: Electrical Distributor - Sparks Flying, But Wrong Direction

Updated 8 Oct 2025

HOLD rating with $3.28 fair value vs $3.73 current price. Revenue growth moderating to 5.7% CAGR with margin compression pressures.

View note
ina

INA: Lifestyle Communities Developer - Demographics Can't Save Overpriced Dreams

Updated 8 Oct 2025

HOLD rating with $3.60 fair value vs $5.96 current price. Strong demographics offset by execution risks and regulatory headwinds.

View note
imd

IMD: Mining Tech Pioneer - Digital Dreams Meet Drilling Reality

Updated 8 Oct 2025

Mining technology leader trading at 44% premium to $2.36 fair value. Strong 29.3% EBITDA margins, 490+ patents, but execution risks from three simultaneous acquisitions amid uncertain exploration recovery.

View note
igl

IGL: Print Giant - Transformation's the New Black

Updated 8 Oct 2025

IVE Group trades at $2.99 vs fair value $8.19, offering 174% upside through portfolio transformation from print to packaging/logistics. Market leader with strong execution track record.

View note
idx

IDX: Diagnostic Imaging Giant - Leveraged to the Hilt, Priced for Perfection

Updated 8 Oct 2025

Australia's #2 diagnostic imaging provider trading at 129% premium to $1.16 fair value. High leverage, workforce constraints, and technology disruption create asymmetric downside risk.

View note
ibx

IBX: Biotech Bubble - MagSense® Makes No Sense at These Levels

Updated 8 Oct 2025

Clinical-stage biotechnology company trading at $1.62 vs fair value $0.13, facing 65% Phase 2 failure probability with extreme dilution risk ahead.

View note
hvn

HVN: Retail Giant - Peak Margins, Property Peaks, and Painful Reality Checks

Updated 8 Oct 2025

Harvey Norman trades at $7.29 vs $3.13 fair value (57% overvalued) with unsustainable margins and property cycle risks creating compelling value opportunity

View note
hdn

HDN: Daily Needs REIT - Pipeline's Running Dry, Premium's Running High

Updated 8 Oct 2025

Trading at $1.00 vs fair value $0.88. Business quality 5.9/10, EBITDA margins compressing 49.9% to 44.7%. Development pipeline finite, competitive moat narrowing 4-6 years.

View note
gwa

GWA: Water Solutions Giant - Plumbing the Depths of Value

Updated 8 Oct 2025

HOLD rating with $2.26 fair value vs $2.65 current price. Strong 5.85% dividend yield offset by customer concentration risks and margin compression pressures.

View note
gqg

GQG: Global Asset Manager - Defensive Genius or Margin Mirage?

Updated 8 Oct 2025

HOLD rating with $1.47 fair value vs $1.757 current price. Exceptional 76% EBITDA margins offset by defensive positioning headwinds and succession risk.

View note